An overview of international literature from cystic fibrosis registries. Part 4: Update 2011

• Published in: Journal of cystic fibrosis 2012-12, Vol.11 (6), p.480-493
• Main Authors: Salvatore, Donatello, Buzzetti, Roberto, Baldo, Ermanno, Furnari, Maria Lucia, Lucidi, Vincenzina, Manunza, Daniela, Marinelli, Italo, Messore, Barbara, Neri, Anna Silvia, Raia, Valeria, Mastella, Gianni
• Format: Article
• Language: English
• Subjects: CF related diabetes; Cystic fibrosis; Cystic Fibrosis - epidemiology; Cystic Fibrosis - therapy; Demographics; Diagnosis factors; Epidemiology; Gender gap; Humans; Incidence; Internationality; Lung disease factors; Microbiology; Nutrition; Patient registry; Prevalence; Pulmonary/Respiratory; Registries - statistics & numerical data; Socioeconomic status; Therapy evaluation
• ISSN: 1569-1993; 1873-5010
• DOI: 10.1016/j.jcf.2012.07.005

Abstract A total of 53 national cystic fibrosis (CF) patient registry studies published between July 2008 and November 2011 have been reviewed, focusing on the following topics: CF epidemiology, nutrition, microbiology, clinical complications, factors influencing diagnosis and lung disease, effects of socioeconomic status, therapeutic strategy evaluation, clinical trial methodology. The studies describe the clinical characteristics of CF patients, the incidence and prevalence of disease and role of gender gap, as well as the influence of socioeconomic status and environmental factors on clinical outcomes, covering a variety of countries and ethnic groups. Original observations describe patients as they get older, with special reference to the adult presentation of CF and long-term survival. Methodological aspects are discussed, covering the design of clinical trials, survival analysis, auxometry, measures of quality of life, follow up of lung disease, predictability of disease progression and life expectancy. Microbiology studies have investigated the role of selected pathogens, such as Burkholderia species and MRSA. Pulmonary exacerbations are discussed both as a factor influencing morbidity and an endpoint in clinical trials. Finally, some studies give insights on complications, such as CF-related diabetes and hemoptysis, and emerging problems, such as chronic nephropathy.